IFNG and cancer: Based on these observations, we wondered whether it is possible to trigger IFNγ-independent expression of HLA-I in cancer cells by using available drugs, which could potentially improve the efficacy of ICI therapies in tumors that have mutations that render them insensitive to IFNγ.